Loading patent…
AssigneeThe Dow Chemical Company
InventorsPeter S. Mezes, Brian B. Gourlie, Mark W. Rixon, Jeffrey Schlom, Donald A. Kaplan, W. H. Kerr Anderson
Estimating the term…
This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have (1) high affinity animal VH and VL sequences which mediate TAG-72 binding and (2) human CH and CL regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human CH and CL antibody domains. The nucleotide and amino acid sequences of VHαTAG VH, CC46 VH, CC49H, CC83 VH, and CC92 VH, and CC49L, CC83 VL, and CC92 VL idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies.
A DNA sequence encoding a chimeric antibody heavy chain or a chimeric antigen-binding fragment thereof, said heavy chain having the amino acid sequence of a chimeric antibody heavy chain produced by any one of the cell lines CH44-1 (ATCC HB9884), CH44-2 (ATCC HB 9880), CH44-4 (ATCC HB 9877), CH88-1 (ATCC HB 9882), CH88-2 (ATCC HB 9881), CH88-3 (ATCC HB 9876), CH88-4 (ATCC HB9874), CH84-1 (ATCC HB 9883), CH84-2 (ATCC HB 9879), CH84-3 (ATCC HB 9878), or CH84-4 (ATCC HB 9875), the heavy chain having the ability to combine with an anti-TAG-72 antibody light chain to form a binding site having an affinity for TAG-72 which is at least 25% greater than that of the binding site of B72.3.
DNA encoding a chimeric antibody or chimeric antibody fragment thereof, said:
A cell having all the identifying characteristics of a cell selected from the group consisting of CH44-1, CH44-2, CH44-4, CH88-1, CH88-2, CH88-3, CH88-4, CH84-1, CH84-2, CH84-3, and CH84-4.
Dependencies are inferred from the claim text.